Cartesian Therapeutics, Inc. (RNAC) shares ended the last trading session 10.3% higher at $7.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.9% loss over the past four weeks.
Last month, the company reported robust financial results for the fourth quarter and full-year 2025, while also providing key pipeline goals and updates for 2026. This might have been driving the recent share price rally.
This company is expected to post quarterly loss of $0.84 per share in its upcoming report, which represents a year-over-year change of -23.5%. Revenues are expected to be $0.43 million, down 61.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Cartesian Therapeutics, Inc., the consensus EPS estimate for the quarter has been revised 2.5% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on RNAC going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Cartesian Therapeutics, Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Precision BioSciences (DTIL), another stock in the same industry, closed the last trading session 4.7% higher at $7.88. DTIL has returned 12.1% in the past month.
For Precision BioSciences, the consensus EPS estimate for the upcoming report has changed +40.2% over the past month to -$0.27. This represents a change of +87.8% from what the company reported a year ago. Precision BioSciences currently has a Zacks Rank of #3 (Hold).
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Cartesian Therapeutics, Inc. (RNAC) : Free Stock Analysis Report
Precision BioSciences, Inc. (DTIL) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
